AQS.V - Aequus Pharmaceuticals Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.1600
-0.0100 (-5.88%)
At close: 11:48AM EST
Stock chart is not supported by your current browser
Previous Close0.1700
Open0.1600
Bid0.16 x 0
Ask0.16 x 0
Day's Range0.1600 - 0.1650
52 Week Range0.1450 - 0.4500
Volume69,500
Avg. Volume87,992
Market Cap12.87M
Beta (3Y Monthly)-0.02
PE Ratio (TTM)N/A
EPS (TTM)-0.04
Earnings DateNov 27, 2018 - Dec 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
  • GlobeNewswireyesterday

    Aequus Signs Term Sheet with European Partner for a Preservative Free Therapeutic in Ophthalmology  

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of a term sheet for an exclusive license in Canada of an undisclosed preservative free ophthalmic therapeutic with a European partner. The preservative free therapeutic is a prescription product, currently approved in certain countries in Europe. Aequus has previously met with Health Canada to receive regulatory guidance regarding this therapeutic and expects to submit an application for regulatory approval in the second half of 2019 for this product, with minimal additional analytical data required to complete the data package.

  • GlobeNewswire19 days ago

    Aequus Reports Largest Quarterly Revenue in Company History and Provides Management Update

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three and nine months ended September 30, 2018 and associated Company developments. Year to date revenue for the nine months ended September 30, 2018 of $1,173,013, a 52% increase over the same period in 2017. Decrease in net losses of 31% over the same quarter last year, and an overall 34% decrease in losses for nine months ended September 30 when compared to the same time period in 2017.

  • Is Aequus Pharmaceuticals Inc’s (CVE:AQS) CEO Being Overpaid?
    Simply Wall St.21 days ago

    Is Aequus Pharmaceuticals Inc’s (CVE:AQS) CEO Being Overpaid?

    Doug Janzen has been the CEO of Aequus Pharmaceuticals Inc (CVE:AQS) since 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then Read More...

  • What Kind Of Shareholders Own Aequus Pharmaceuticals Inc (CVE:AQS)?
    Simply Wall St.last month

    What Kind Of Shareholders Own Aequus Pharmaceuticals Inc (CVE:AQS)?

    A look at the shareholders of Aequus Pharmaceuticals Inc (CVE:AQS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, Read More...

  • GlobeNewswirelast month

    Aequus Strengthens Clinical Experience on Strategic Advisory Board in Ophthalmology, and Adds Commercial and Regulatory Expertise

    VANCOUVER, British Columbia, Nov. 15, 2018 -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a.

  • GlobeNewswirelast month

    Aequus Hosts Live Webinar Demonstrating the Zepto® Capsulotomy System, Led by Dr. Ike Ahmed

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, is pleased to announce the successful presentation of a live webinar demonstrating the Zepto®  Precision Pulse Capsulotomy (“Zepto”) device’s ability to address challenging capsulotomy cases during cataract surgery. The webinar, hosted by Dr. Ike Ahmed, took place on Monday, November 12 and was attended by ophthalmologists across Canada interested in learning more about the product’s features and use within the clinic.

  • GlobeNewswirelast month

    Aequus forms Strategic Advisory Board in Ophthalmology, Chaired by Dr. Ike Ahmed

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced the formation of a strategic advisory board in ophthalmology with the appointment of its first two members, Dr. Ike Ahmed of the Prism Eye Institute joining as Chairman, and Dr. Rosa Braga-Mele of the University of Toronto. Aequus has formed the Advisory Board to assist in assessing and rationalizing the many ophthalmology pipeline opportunities, both in therapeutics and medical devices, available to the Company.